

[ Wed, Sep 18th 2024
] - WOPRAI

[ Fri, May 10th 2024
] - WOPRAI

[ Thu, Aug 10th 2023
] - WOPRAI

[ Tue, May 09th 2023
] - WOPRAI

[ Tue, Aug 09th 2022
] - WOPRAI

[ Wed, Mar 16th 2022
] - WOPRAI


[ Thu, Nov 11th 2021
] - WOPRAI

[ Tue, Nov 02nd 2021
] - WOPRAI


[ Tue, Oct 26th 2021
] - WOPRAI

[ Thu, Jul 29th 2021
] - WOPRAI


[ Mon, May 10th 2021
] - WOPRAI

[ Fri, May 07th 2021
] - WOPRAI

[ Fri, Mar 26th 2021
] - WOPRAI

[ Mon, Mar 08th 2021
] - WOPRAI

[ Tue, Feb 23rd 2021
] - WOPRAI

[ Mon, Jan 25th 2021
] - WOPRAI

[ Thu, Oct 01st 2020
] - WOPRAI

[ Mon, Aug 03rd 2020
] - WOPRAI

[ Fri, May 08th 2020
] - WOPRAI

[ Fri, Feb 28th 2020
] - WOPRAI


[ Thu, Nov 07th 2019
] - WOPRAI

[ Fri, May 10th 2019
] - WOPRAI



[ Tue, Mar 14th 2017
] - WOPRAI


[ Wed, Jun 03rd 2015
] - WOPRAI
Elliot Wilbur Maintained (ANIP) at Buy with Increased Target to $83 on, Sep 18th, 2024
Elliot Wilbur of Raymond James, Maintained "ANI Pharmaceuticals, Inc." (ANIP) at Buy with Increased Target from $81 to $83 on, Sep 18th, 2024.
Elliot has made no other calls on ANIP in the last 4 months.
There are 2 other peers that have a rating on ANIP. Out of the 2 peers that are also analyzing ANIP, 1 agrees with Elliot's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gregory Fraser of "Truist Securities" Downgraded from Strong Buy to Hold and Decreased Target to $60 on, Wednesday, September 11th, 2024
This is the rating of the analyst that currently disagrees with Elliot
- Oren Livnat of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $94 on, Tuesday, September 17th, 2024